Buclizine

Names

[ CAS No. ]:
82-95-1

[ Name ]:
Buclizine

[Synonym ]:
Buclozin
1-<4-Chlor-benzhydryl>-4-<4-tert.-butyl-benzyl>-piperazin
Histabuticine
BUCLIZINE
AH 2526
Buclifen
aphilan-rbase
Postafen
Bucladin
Hitabutyzyne

Biological Activity

[Description]:

Buclizine is an orally active antihistamine antiallergic compound. Buclizine is a potent teratogen in the rat and shows anti-tumor activity[1][2][3].

[Related Catalog]:

Research Areas >> Cancer

Signaling Pathways >> Immunology/Inflammation >> Histamine Receptor

Research Areas >> Inflammation/Immunology

Signaling Pathways >> GPCR/G Protein >> Histamine Receptor

[In Vitro]

Buclizine (0.1-100 μM; 72 h) inhibits growth of MCF-7 cells[2]. Buclizine (9.625-77 μM; 72 h) arrests the cell cycle in the G1 phase in a dose-dependent manner[2]. Buclizine (0-75 μM; 72 h) decreases TCTP (translationally controlled tumor protein) and cell cycle regulatory proteins expression in MCF-7 cells, increases pro-apoptotic MCL-1S expression[2]. Cell Proliferation Assay[2] Cell Line: MCF-7 cells Concentration: 0-100 μM Incubation Time: 72 hours Result: Showed considerable growth inhibition (IC50=19.18 μM). Cell Cycle Analysis[2] Cell Line: MCF-7 cells Concentration: 9.625, 19.25, 38.5, and 77 μM Incubation Time: 72 hours Result: Increased the percentages of cells in the G1 phase to 73% at 77 μM. Western Blot Analysis[2] Cell Line: MCF-7 cells Concentration: 0-75 μM Incubation Time: 72 hours Result: Decreased TCTP expression by 40% at 75 μM. Decreased cyclin D1, cyclin D3, CDK2 and CDK4 expression after 72 h.

[In Vivo]

Buclizine dihydrochloride (30-200 mg/kg; tenth to fifteenth and twelfth to fifteenth days of gestation) shows potent teratogens in the rat[3]. Animal Model: Eighty-seven mature female rats weighing 240±20 grams[3] Dosage: 30, 40, 60, 100, and 200 mg/kg Administration: 30-200 mg/kg; tenth to fifteenth and twelfth to fifteenth days of gestation Result: Resulted in malformations in 100% of the young at a dose level of 60-100 mg/kg.

[References]

[1]. Gamal A E Mostafa, et al. Buclizine. Profiles Drug Subst Excip Relat Methodol. 2011;36:1-33.

[2]. Ean-Jeong Seo, et al. Interaction of antihistaminic drugs with human translationally controlled tumor protein (TCTP) as novel approach for differentiation therapy. Oncotarget. 2016 Mar 29;7(13):16818-39.

[3]. C T King, et al. Teratogenic effect of buclizine and hydroxyzine in the rat and chlorcyclizine in the mouse. Am J Obstet Gynecol. 1966 May 1;95(1):109-11.

Chemical & Physical Properties

[ Molecular Formula ]:
C₂₈H₃₃ClN₂

[ Molecular Weight ]:
433.02800

[ Exact Mass ]:
432.23300

[ PSA ]:
6.48000

[ LogP ]:
6.42050

[ Storage condition ]:
2-8°C

Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :: TL0260000

CHEMICAL NAME :: Piperazine, 1-(p-tert-butylbenzyl)-4-(p-chloro-alpha-phenylbenzyl )-

CAS REGISTRY NUMBER :: 82-95-1

BEILSTEIN REFERENCE NO. :: 0349567

LAST UPDATED :: 199612

DATA ITEMS CITED :: 1

MOLECULAR FORMULA :: C28-H33-Cl-N2

MOLECULAR WEIGHT :: 433.08

WISWESSER LINE NOTATION :: T6N DNTJ AYR&R DG& D1R DX1&1&1

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 320 mg/kg

SEX/DURATION :: female 13-16 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - homeostasis

REFERENCE :: TXAPA9 Toxicology and Applied Pharmacology. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1959- Volume(issue)/page/year: 17,67,1970

Safety Information

[ Hazard Codes ]:
Xi

[ HS Code ]:
2933599090

Synthetic Route

Click to get detail synthetic route

Precursor & DownStream

Precursor

DownStream

Customs

[ HS Code ]: 2933599090

[ Summary ]:
2933599090. other compounds containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%